This inventor holds 1 USPTO granted patent and 8 published patent applications and 1 EPO patent. Top assignees: Genfleet Therapeutics (Shanghai) Inc., Zhejiang Genfleet Therapeutics Co., Ltd.. Active years: 2024.
Company Filing History:
1 out of 7 
1 out of 2 Years Active: 2024
Title: Lijian Cai: Innovator in Pharmaceutical Compounds
Introduction
Lijian Cai is a prominent inventor based in Shanghai, China. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that target specific genetic mutations.
Latest Patents
Lijian Cai holds a patent for a substituted heterocyclic fused cyclic compound. This compound is characterized by its selective inhibitory effect on KRAS gene mutations. The patent also covers the preparation method for this compound and its pharmaceutical applications, particularly in the development of cancer drugs.
Career Highlights
Throughout his career, Lijian Cai has worked with notable companies in the pharmaceutical industry. He has been associated with Genfleet Therapeutics and Zhejiang Genfleet Therapeutics Co., Ltd. His work has focused on innovative solutions for complex medical challenges.
Collaborations
Lijian Cai has collaborated with esteemed colleagues in his field, including Fusheng Zhou and Tao Jiang. These partnerships have contributed to the advancement of research and development in pharmaceutical applications.
Conclusion
Lijian Cai's work exemplifies the impact of innovation in the pharmaceutical industry. His contributions to the development of targeted cancer therapies highlight the importance of research in improving health outcomes.